The type I FLT3 inhibitor XL999 overrides secondary FLT3-ITD mutations that arise under gilteritinib and quizartinib treatment in acute myeloid leukemia. (PubMed, Mol Biomed) - Sep 5, 2026 - "Furthermore, XL999 demonstrated robust efficacy in patient-derived xenograft models, complemented by a favorable oral bioavailability profile. Together, these findings suggest that XL999 may represent an orally bioavailable FLT3 inhibitor with the potential to overcome clinically relevant secondary resistance mutations in FLT3-ITD-positive AML, supporting its further investigation as a therapeutic candidate."
Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3
|
|
Fangfang Yang; Jiajun He; Jiaqi Fan; Peihong Wang; Qi Xiang; Shiyang Wang; Shunqing Wang; Yuping Zhang; Yvyin Zhang; Zhiwei Zhong
|